Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by Aditxt, Inc.

< Previous 1 2 3 Next >
Aditxt Subsidiary Pearsanta Receives IRB Approval to Initiate Clinical Study of Blood-Based Diagnostic for Endometriosis with Patient Enrollment Planned to Begin in May 2025
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
Aditxt Weekly Update to Highlight Recent Events, Including Regaining Compliance with Nasdaq Listing Requirements
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
Aditxt, Inc. (NASDAQ: ADTX) Regains Compliance with Nasdaq Listing Requirements
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
Appili President and CEO, Don Cilla Will Join Aditxt Co-founder and CEO, Amro Albanna, at the Aditxt Weekly Update on April 4, 2025
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
Upcoming Aditxt Weekly Update to Highlight Pearsanta’s Acquisition of the Adductomics-Based CaSe Platform and its Potential for Early Cancer Detection
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
Aditxt Subsidiary Pearsanta Completes the Acquisition of Proprietary Adductomics Technology to Develop and Advance the Platform Toward Clinical and Commercial Applications for Monitoring Early Signs of Increased Cancer Risk
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
Aditxt Provides Business Status Overview and Announces Launch of Aditxt Weekly Update Starting Friday, March 21, 2025
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-250 Reverse Stock Split Effective at the Open of Trading on March 17, 2025
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
Aditxt Subsidiary Adimune to Ship Drug Substances for Final Drug Product Formulation of ADI-100 Ahead of Planned Clinical Trials in Type 1 Diabetes and Psoriasis in Germany, and Stiff Person Syndrome at the Mayo Clinic in the U.S.
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
Aditxt Subsidiary Pearsanta Engages Dominari Securities for its Initial Public Offering, to Drive U.S. and Global Commercial Launch of Early Cancer Detection and Diagnosis Targeted for H2 2025
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
Aditxt to Host Fireside Chat on Friday, February 21st at 11:30 AM Eastern Time
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
Aditxt’s Board of Directors Unanimously Approve Positioning Pearsanta for IPO to Support Global Launch of its Early Cancer Detection Platform
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
Aditxt's Subsidiary Adimune Successfully Completes Preclinical Efficacy and Safety Studies for Its Immune Modulation Therapeutic ADI Platform, Advancing Toward First-in-Human Clinical Trials
From Aditxt, Inc.
Via Business Wire
Tickers ADTX APLIF EVFM OTC
Aditxt Provides Update on Equity Line of Credit, ATM Usage, and Outstanding Number of Shares
From Aditxt, Inc.
Via Business Wire
Tickers ADTX APLIF EVFM OTC
Aditxt’s Target Acquisition Appili Therapeutics Announces Results of Special Meeting of Shareholders
From Aditxt, Inc.
Via Business Wire
Tickers ADTX APLIF OTC TSX:APLI
Aditxt Acquisition Target Evofem Biosciences Secures Investor Support Through Voting Agreements for Merger with Aditxt's Subsidiary Adifem
From Aditxt, Inc.
Via Business Wire
Tickers ADTX APLIF EVFM OTC
Aditxt’s Target Acquisition Appili Therapeutics Announces Alignment with FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission
From Aditxt, Inc.
Via Business Wire
Tickers ADTX APLIF OTC TSX:APLI
Aditxt To Host Virtual Stakeholder Update and Q&A Session on Friday, November 1, 2024, at 11:30 AM Eastern Time
From Aditxt, Inc.
Via Business Wire
Tickers ADTX APLIF EVFM OTC
Sylvia Hermina Joins Aditxt’s Board of Directors, Elevating Leadership with Broader Perspectives
From Aditxt, Inc.
Via Business Wire
Tickers ADTX APLIF EVFM OTC
Aditxt Completes Final Equity Investment and Key Milestone Under the Amended and Restated Merger Agreement with Evofem
From Aditxt, Inc.
Via Business Wire
Tickers ADTX APLIF EVFM OTC
Aditxt to Host a Virtual Fireside Chat with Aditxt CEO Amro Albanna and Evofem CEO Saundra Pelletier, Moderated by MD & Media Personality Dr. Drew Pinsky, on October 28, 2024, at 11:30 AM Eastern Time
From Aditxt, Inc.
Via Business Wire
Tickers ADTX EVFM
Aditxt’s Acquisition Target Appili Therapeutics Will Hold a Special Meeting of Shareholders on November 6, 2024, to Vote on the Transaction and Secure Appili’s Shareholder Approval
From Aditxt, Inc.
Via Business Wire
Tickers ADTX APLIF OTC TSX:APLI
Aditxt To Host Stakeholder Update and Q&A Session on Friday, October 11, 2024, at 11:30 AM Eastern Daylight Time
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
Aditxt Completes Third Parent Equity Investment Under Amended and Restated Merger Agreement With Evofem
From Aditxt, Inc.
Via Business Wire
Tickers ADTX EVFM
Aditxt Delivers Shareholder Update and 2024 Year-End Plan
From Aditxt, Inc.
Via Business Wire
Tickers ADTX APLIF EVFM OTC
Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-40 Reverse Stock Split Effective at the Open of Trading on October 2, 2024
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
Evofem Biosciences Files Preliminary Proxy for Stockholder Approval of the Acquisition by Aditxt
From Aditxt, Inc.
Via Business Wire
Tickers ADTX EVFM
Aditxt’s Subsidiary Pearsanta to Collaborate with Evofem Biosciences for Targeted U.S. Launch of Endometriosis Diagnostic in Mid-2025
From Aditxt, Inc.
Via Business Wire
Tickers ADTX EVFM
Aditxt and Evofem Sign Second Amendment to Amended and Restated Merger Agreement, Target Closing of Acquisition in Fourth Quarter of 2024
From Aditxt, Inc.
Via Business Wire
Tickers ADTX EVFM
Aditxt Subsidiary Pearsanta Submits a Grant Application Seeking to Advance Clinical Trials for Mitomic® Prostate Test, Targeting Early Detection in High-Risk Patients
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.